Construction and validation of a novel disulfidptosis-related lncRNA signature for prognostic prediction in lung adenocarcinoma

Abstract

Disulfidptosis is a novel type of cell death caused by disulfide stress and is distinct from other known forms of cell death, including cuproptosis, ferroptosis, pyroptosis, necroptosis, and apoptosis. Transcriptome data and clinical information of 503 LUAD patients was extracted from The Cancer Genome Atlas (TCGA) database. A nomogram was constructed with the risk score based on the expression levels of the 4 disulfidptosis-associated lncRNAs and the clinical characteristics and was according to the results from the univariate and multivariate Cox regression, minimal absolute contraction, and least absolute shrinkage and selection operator (LASSO) regression analyses.Differences in the tumor immune microenvironment (TIME), tumor mutation burden (TMB), and chemotherapeutic treatment sensitivity were compared between the high- and low-risk LUAD patients. LncRNA ARRDC1-AS1 was highly expressed in the LUAD cell lines (A549 and H1299) compared to the BEAS2B cell line (normal lung epithelial cells). Knockdown of ARRDC1-AS1 significantly reduced in vitro proliferation, migration, and invasiveness of A549 cells. LncRNA ARRDC1-AS1 is a promising prognosis prediction biomarker and a therapeutic target in LUAD.